David A. Santos
Executive VP & Chief Commercial OfficerMr. David A. Santos, also known as Dave, serves as Executive Vice President and Chief Commercial Officer at Rigel Pharmaceuticals, Inc. since August 2020. Mr. Santos joins Rigel with extensive commercial experience in the biopharmaceutical industry with companies such as Bristol-Myers Squibb, Lilly, Genentech, and most recently Jazz Pharmaceuticals, where he led the Hematology/Oncology Business Unit. Mr. Santos joined Rigel from Jazz Pharmaceuticals, where he held the role of hematology/oncology business unit head, responsible for leading us commercialization of the oncology portfolio from January 2016 to July 2020. He has a robust track record in sales and marketing leadership roles, building commercial capabilities, and growing brands in the hematology-oncology area, where he has spent most of his career. During his tenure at Jazz, he successfully grew the business unit through three launches to eventually have four promoted products in the leukemia, transplant and lung cancer markets. Prior to joining Jazz, from January 2014 to May 2015, Mr. Santos served as Vice President of sales and marketing for Medivation (now Pfizer), responsible for commercializing Xtandi for metastatic prostate cancer, and Vice President, kinase inhibitor franchise for Onyx (now Amgen), responsible for leading sales and marketing efforts with Nexavar and Stivarga. Before his work at Onyx, Mr. Santos served for nearly 9 years in roles of increasing responsibility at Genentech, Inc., where he launched and held key commercial leadership roles on several successful brands, including Avastin, Herceptin and Tarceva. Mr. Santos also held marketing and sales roles at Lilly Oncology and Bristol-Myers Squibb, where he started his pharmaceutical sales career. He received his BS in chemistry from St. Louis University.
Positions
- Company NameRigel Pharmaceuticals, Inc.Stock CodeRIGLPositionExecutive VP & Chief Commercial OfficerColleagues
- RRRaul R. RodriguezPresident, CEO & Director
- GAGregory Anthony LapointeIndependent Chairman of the Board
- DLDean L. SchornoExecutive VP & CFO
- RJRaymond J. FureyExecutive VP, Chief Compliance Officer, General Counsel & Corporate Secretary
- ALAlison L. HannahExecutive VP & Chief Medical Officer
- WHWalter H. MoosIndependent Director
- JWJane WasmanIndependent Director
- KAKamil Ali JacksonIndependent Director
